Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 2083
Molecular formula: C13H21NO3
IUPAC: 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
Source: PC-ALBUTEROL
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nonpeptide β2-adrenergic agonist causing bronchodilation; systemic effects can also occur.
Evidence and critical reading
Reported scientific and empirical uses
Respiratory function
Inhaled medicines for bronchospasm. Presence in a fat-promoted blend does not make the blend an authorized metabolic treatment.
Human evidence
Inhaler labeling identifies amount per actuation and pulmonary route. It cannot infer an injectable regimen from an ingredient list.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Inhaler labeling identifies amount per actuation and pulmonary route. It cannot infer an injectable regimen from an ingredient list.
Inhaler labeling identifies amount per actuation and pulmonary route. It cannot infer an injectable regimen from an ingredient list.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: the cited HFA aerosol is an inhaled medicine for bronchospasm. Its authorization does not cover an injectable fat-reduction blend.
Adverse effects and unknowns
Tachycardia, tremor and hypokalemia; other sympathomimetics may increase effects. Beta blockers and certain antidepressants/diuretics require label review.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Albuterol · 951 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07877519 · Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT03460704 · Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.Registry status: TerminatedLast update posted: October 15, 2026Query verification: October 16, 2026
NCT05776927 · A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.Registry status: RecruitingLast update posted: October 15, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-ALBUTEROL
October 16, 2026
- REG-ALBUTEROL
DailyMed: Albuterol sulfate HFA inhalation aerosol
October 16, 2026
- SEARCH-PUBMED-albuterol
PubMed/MED targeted search: TITLE_ABS:albuterol AND TITLE_ABS:asthma AND TITLE_ABS:randomized
October 16, 2026